197 related articles for article (PubMed ID: 29793804)
21. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
[TBL] [Abstract][Full Text] [Related]
22. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract][Full Text] [Related]
23. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
25. An integrated molecular profile of endometrioid ovarian cancer.
Pierson WE; Peters PN; Chang MT; Chen LM; Quigley DA; Ashworth A; Chapman JS
Gynecol Oncol; 2020 Apr; 157(1):55-61. PubMed ID: 32139151
[TBL] [Abstract][Full Text] [Related]
26. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
27. L1-CAM in Mucinous Ovarian Carcinomas and Borderline Tumors: Impact on Tumor Recurrence and Potential Role in Tumor Progression.
Wiedenhoefer R; Schmoeckel E; Grube M; Sulyok M; Pasternak I; Beschorner C; Greif K; Brucker S; Mayr D; Kommoss S; Fend F; Staebler A; Fischer AK
Am J Surg Pathol; 2023 May; 47(5):558-567. PubMed ID: 36852510
[TBL] [Abstract][Full Text] [Related]
28. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
[TBL] [Abstract][Full Text] [Related]
29. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
[TBL] [Abstract][Full Text] [Related]
30. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
31. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
32. Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer.
Watanabe T; Nanamiya H; Endo Y; Kojima M; Nomura S; Furukawa S; Soeda S; Tamura H; Ryufuku M; Tanaka D; Isogai T; Imai JI; Watanabe S; Fujimori K
J Ovarian Res; 2021 Oct; 14(1):129. PubMed ID: 34615547
[TBL] [Abstract][Full Text] [Related]
33. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
[TBL] [Abstract][Full Text] [Related]
34. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
35. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
36. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.
Schultheis AM; Ng CK; De Filippo MR; Piscuoglio S; Macedo GS; Gatius S; Perez Mies B; Soslow RA; Lim RS; Viale A; Huberman KH; Palacios JC; Reis-Filho JS; Matias-Guiu X; Weigelt B
J Natl Cancer Inst; 2016 Jun; 108(6):djv427. PubMed ID: 26832770
[TBL] [Abstract][Full Text] [Related]
37. Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries.
Heinzelmann-Schwarz VA; Scolyer RA; Scurry JP; Smith AN; Gardiner-Garden M; Biankin AV; Baron-Hay S; Scott C; Ward RL; Fink D; Hacker NF; Sutherland RL; O'Brien PM
J Clin Pathol; 2007 Jun; 60(6):622-6. PubMed ID: 16822880
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic options for mucinous ovarian carcinoma.
Gorringe KL; Cheasley D; Wakefield MJ; Ryland GL; Allan PE; Alsop K; Amarasinghe KC; Ananda S; Bowtell DDL; Christie M; Chiew YE; Churchman M; DeFazio A; Fereday S; Gilks CB; Gourley C; Hadley AM; Hendley J; Hunter SM; Kaufmann SH; Kennedy CJ; Köbel M; Le Page C; Li J; Lupat R; McNally OM; McAlpine JN; Pyman J; Rowley SM; Salazar C; Saunders H; Semple T; Stephens AN; Thio N; Torres MC; Traficante N; Zethoven M; Antill YC; Campbell IG; Scott CL
Gynecol Oncol; 2020 Mar; 156(3):552-560. PubMed ID: 31902686
[TBL] [Abstract][Full Text] [Related]
39. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
40. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]